MCID: DYS011
MIFTS: 43

Dyskinesia of Esophagus

Categories: Gastrointestinal diseases

Aliases & Classifications for Dyskinesia of Esophagus

MalaCards integrated aliases for Dyskinesia of Esophagus:

Name: Dyskinesia of Esophagus 12 15
Esophageal Motility Disorders 56 45 74
Esophageal Motility Disorder 12
Oesophageal Motor Disorder 12
Dyskinesia of Oesophagus 12
Oesophageal Dysmotility 12
Esophageal Dysmotility 12
Esophageal Spasm 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9192
ICD9CM 36 530.5
MeSH 45 D015154
ICD10 34 K22.4

Summaries for Dyskinesia of Esophagus

MalaCards based summary : Dyskinesia of Esophagus, also known as esophageal motility disorders, is related to crest syndrome and esophagitis, eosinophilic, 1, and has symptoms including spasm An important gene associated with Dyskinesia of Esophagus is TEF (TEF Transcription Factor, PAR BZIP Family Member). The drugs Methylene blue and Domperidone have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and bone.

Related Diseases for Dyskinesia of Esophagus

Diseases related to Dyskinesia of Esophagus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 119)
# Related Disease Score Top Affiliating Genes
1 crest syndrome 32.3 CENPB TOP1 UBTF
2 esophagitis, eosinophilic, 1 30.7 ATP12A ATP4A
3 peptic esophagitis 30.3 ATP12A ATP4A
4 hernia, hiatus 30.2 ATP12A ATP4A
5 scleroderma, familial progressive 30.2 RNPC3 TOP1
6 rheumatic disease 29.5 CENPB RNPC3 TOP1
7 connective tissue disease 29.5 CENPB RNPC3 TOP1
8 paroxysmal nocturnal hemoglobinuria 11.2
9 esophagitis 10.3
10 fungal esophagitis 10.3 ATP12A ATP4A
11 diclofenac allergy 10.3 ATP12A ATP4A
12 gastroduodenal crohn's disease 10.3 ATP12A ATP4A
13 neonatal candidiasis 10.3 ATP12A ATP4A
14 photoallergic dermatitis 10.3 ATP12A ATP4A
15 squamous papillomatosis 10.3 ATP12A ATP4A
16 toxic megacolon 10.3 ATP12A ATP4A
17 aspiration pneumonitis 10.3 ATP12A ATP4A
18 gastrointestinal neuroendocrine benign tumor 10.3 ATP12A ATP4A
19 granulomatous gastritis 10.3 ATP12A ATP4A
20 esophageal candidiasis 10.3 ATP12A ATP4A
21 gastric neuroendocrine neoplasm 10.3 ATP12A ATP4A
22 acute laryngitis 10.3 ATP12A ATP4A
23 laryngitis 10.3 ATP12A ATP4A
24 duodenitis 10.3 ATP12A ATP4A
25 rumination disorder 10.3 ATP12A ATP4A
26 active peptic ulcer disease 10.3 ATP12A ATP4A
27 congenital disorder of deglycosylation 10.3 ATP12A ATP4A
28 bladder calculus 10.3 ATP12A ATP4A
29 ischemic neuropathy 10.3 ATP12A ATP4A
30 bile reflux 10.3 ATP12A ATP4A
31 capillary disease 10.3 ATP12A ATP4A
32 anismus 10.3 ATP12A ATP4A
33 postsurgical hypothyroidism 10.3 ATP12A ATP4A
34 lymphocytic colitis 10.3 ATP12A ATP4A
35 clostridium difficile colitis 10.3 ATP12A ATP4A
36 diarrhea 1, secretory chloride, congenital 10.3 ATP12A ATP4A
37 gastroesophageal reflux 10.3
38 microscopic colitis 10.3 ATP12A ATP4A
39 laryngeal tuberculosis 10.3 ATP12A ATP4A
40 chronic laryngitis 10.3 ATP12A ATP4A
41 eosinophilic gastritis 10.3 ATP12A ATP4A
42 esophagus adenocarcinoma 10.2 ATP12A ATP4A
43 chronic intestinal vascular insufficiency 10.2 ATP12A ATP4A
44 polyposis, skin pigmentation, alopecia, and fingernail changes 10.2 ATP12A ATP4A
45 jejunoileitis 10.2 ATP12A ATP4A
46 pancreatic steatorrhea 10.2 ATP12A ATP4A
47 esophageal varix 10.2 ATP12A ATP4A
48 superior mesenteric artery syndrome 10.2 ATP12A ATP4A
49 gastric lymphoma 10.2 ATP12A ATP4A
50 lower urinary tract calculus 10.2 ATP12A ATP4A

Comorbidity relations with Dyskinesia of Esophagus via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Anxiety
Bronchitis Chronic Myocardial Ischemia
Deficiency Anemia Dysthymic Disorder
Esophageal Disease Esophagitis
Gastroesophageal Reflux Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Irritable Bowel Syndrome
Ischemic Heart Disease Megaesophagus
Mitral Valve Disease Osteoporosis
Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Dyskinesia of Esophagus:



Diseases related to Dyskinesia of Esophagus

Symptoms & Phenotypes for Dyskinesia of Esophagus

UMLS symptoms related to Dyskinesia of Esophagus:


spasm

Drugs & Therapeutics for Dyskinesia of Esophagus

Drugs for Dyskinesia of Esophagus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 286)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylene blue Approved, Investigational Phase 4,Not Applicable 61-73-4
2
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 57808-66-9 3151
3
Dopamine Approved Phase 4,Phase 3,Not Applicable 62-31-7, 51-61-6 681
4
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73590-58-6 4594
5
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 117976-89-3 5029
6
Trimebutine Approved Phase 4 39133-31-8
7
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 103577-45-3 3883
8
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 138530-94-6, 103577-45-3 9578005
9
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
10
Calcium polycarbophil Approved Phase 4 126040-58-2
11
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
12
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 102625-70-7 4679
13
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 32051
14
Acetylcholine Approved, Investigational Phase 4,Phase 2,Not Applicable 51-84-3 187
15
Codeine Approved, Illicit Phase 4 76-57-3 5284371
16
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
17
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
18
Magnesium trisilicate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 14987-04-3
19
Aluminum hydroxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 21645-51-2
20
Nortriptyline Approved Phase 4,Phase 2,Phase 3 72-69-5 4543
21
Citalopram Approved Phase 4 59729-33-8 2771
22
Magnesium hydroxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1309-42-8
23
Ethanol Approved Phase 4 64-17-5 702
24
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
25
Metoclopramide Approved, Investigational Phase 4,Phase 3,Not Applicable 364-62-5 4168
26
Famotidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 76824-35-6 3325
27
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-45-6 774
28
Nizatidine Approved Phase 4,Phase 3 76963-41-2 3033637
29
Ranitidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 66357-59-3, 66357-35-5 3001055
30
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2
31
Prucalopride Approved Phase 4 179474-81-8
32
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
33
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
34
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
35
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
36
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
37
Ziprasidone Approved Phase 4 146939-27-7 60854
38
Clozapine Approved Phase 4 5786-21-0 2818
39
Lithium carbonate Approved Phase 4 554-13-2
40
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
41
Clarithromycin Approved Phase 4 81103-11-9 84029
42
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
43
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
44
SB-649868 Experimental, Investigational Phase 4 110-16-7, 110-17-8 444972
45 Mosapride Investigational Phase 4,Not Applicable 112885-41-3
46 Rebamipide Investigational Phase 4 90098-04-7
47
Lafutidine Investigational Phase 4,Phase 3 118288-08-7 5282136
48
Polaprezinc Experimental Phase 4 107667-60-7
49 Dopamine Agents Phase 4,Phase 3,Not Applicable
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 800)
# Name Status NCT ID Phase Drugs
1 Personalized Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01570621 Phase 4
2 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
3 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
4 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
5 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
6 Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
7 Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD Unknown status NCT01882088 Phase 4 Mucofalk
8 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
9 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
10 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Unknown status NCT01503476 Phase 4
11 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
12 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate Unknown status NCT02278081 Phase 4 lansoprazole;placebo
13 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
14 Codeine on Pharyngeal and Esophageal Motility Completed NCT03784105 Phase 4 Codeine Phosphate;Siripus simplex
15 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH
16 The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain Completed NCT01598207 Phase 4 Marinol;Placebo
17 Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets Completed NCT03037606 Phase 4 Rabelis DDR 50 mg Capsules;Pariet 20 mg Enteric Coated Tablets
18 The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity Completed NCT02958046 Phase 4 Lansoprazole/Domperidone
19 Implementation of PPI Medication PGX Testing Completed NCT02794844 Phase 4 Genotype Guided PPI Dosing
20 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
21 The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease Completed NCT02505945 Phase 4 Omeprazole
22 Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously Completed NCT00635414 Phase 4 Esomeprazole;Esomeprazole
23 Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD Completed NCT00410592 Phase 4 Esomeprazole 40mg;Pantoprazole 40mg;Lansoprazole 30mg
24 Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response Completed NCT00392002 Phase 4 Esomeprazole
25 PPI Sequencing Study Completed NCT00384592 Phase 4 Esomeprazole
26 CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing Completed NCT00354757 Phase 4 rabeprazole
27 Symptom Adapted Therapy in GERD Patients Completed NCT00343161 Phase 4 esomeprazole;Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)
28 Validation of RDQ Questionnaire Completed NCT00291746 Phase 4 Esomeprazole
29 Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI) Completed NCT00251732 Phase 4 Standard dose (once daily) PPI plus low-dose antidepressant;Double dose PPI plus evening placebo;Rabeprazole , placebo, placebo
30 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00242736 Phase 4 Esomeprazole
31 Effect of Citalopram on Reflux Episodes in Healthy Volunteers Completed NCT03746691 Phase 4 Citalopram HCl;Placebos
32 Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B Completed NCT03128736 Phase 4 Esomeprazole group;Dexlansoprazole group
33 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
34 Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic Rhinosinusitis Completed NCT03086070 Phase 4 Omeprazole 20mg;Placebo oral capsule
35 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
36 The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity Completed NCT02689999 Phase 4 Dexrabeprazole 10 mg Enteric-Coated Tablets
37 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
38 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
39 BRAVO Study for Functional Dyspepsia Completed NCT01349413 Phase 4 Esomeprazole 20mg
40 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4 Lansoprazole
41 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
42 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Completed NCT00926276 Phase 4
43 Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying Completed NCT01956682 Phase 4
44 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
45 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
46 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
47 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed NCT00660660 Phase 4 Esomeprazole;Placebo
48 Quality of Life Validation in Laryngitis Completed NCT00641264 Phase 4 Omeprazole
49 Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD) Completed NCT00637845 Phase 4 Esomeprazole Magnesium;Lansoprazole
50 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00629564 Phase 4 Esomeprazole;Esomeprazole

Search NIH Clinical Center for Dyskinesia of Esophagus

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: esophageal motility disorders

Genetic Tests for Dyskinesia of Esophagus

Anatomical Context for Dyskinesia of Esophagus

MalaCards organs/tissues related to Dyskinesia of Esophagus:

42
Testes, Lung, Bone, Spinal Cord, Thyroid, Tonsil, Adipocyte

Publications for Dyskinesia of Esophagus

Articles related to Dyskinesia of Esophagus:

(show top 50) (show all 137)
# Title Authors Year
1
Heller Myotomy for Epiphrenic Diverticula Compared to Nondiverticula Esophageal Motility Disorders, A Single Institution Experience and Appraisal of Patient Characteristics, High-Resolution Manometry and Outcomes. ( 30721906 )
2019
2
Peroral endoscopic myotomy is effective and safe in non-achalasia esophageal motility disorders: an international multicenter study. ( 30105290 )
2018
3
Can Eosinophilic Esophagitis Cause Achalasia and Other Esophageal Motility Disorders? ( 30315308 )
2018
4
Gender, medication use and other factors associated with esophageal motility disorders in non-obstructive dysphagia. ( 30151201 )
2018
5
Factors predictive of gastroesophageal reflux disease and esophageal motility disorders in patients with non-cardiac chest pain. ( 29848163 )
2018
6
Clinical outcomes five years after POEM for treatment of primary esophageal motility disorders. ( 28664434 )
2018
7
A Procedure for the Automatic Analysis of High-Resolution Manometry Data to Support the Clinical Diagnosis of Esophageal Motility Disorders. ( 28976308 )
2018
8
Esophageal motility disorders: new perspectives from high-resolution manometry and histopathology. ( 29134329 )
2018
9
Factors Determining the Inter-observer Variability and Diagnostic Accuracy of High-resolution Manometry for Esophageal Motility Disorders. ( 29291608 )
2018
10
Ten Initial Cases of Peroral Endoscopic Myotomy for Treatment of Esophageal Motility Disorders at Okayama University Hospital. ( 29674757 )
2018
11
Advances in Management of Esophageal Motility Disorders. ( 29702296 )
2018
12
Factors Determining the Inter-observer Variability and Diagnostic Accuracy of High-resolution Manometry for Esophageal Motility Disorders. ( 29969864 )
2018
13
Management of esophageal motility disorders in children : a review. ( 30024702 )
2018
14
Overlap Between Gastric and Esophageal Motility Disorders: A Contractual Arrangement? ( 30178282 )
2018
15
Peroral endoscopic myotomy (POEM) is effective in treatment of noncardiac chest pain caused by hypercontractile esophageal motility disorders: results of the POEM-HYPE-Study. ( 30296811 )
2018
16
The Role of Botulinum Toxin Injections for Esophageal Motility Disorders. ( 30406479 )
2018
17
High resolution manometry and new classification of esophageal motility disorders. ( 30701897 )
2018
18
Primary Esophageal Motility Disorders: Beyond Achalasia. ( 28665309 )
2017
19
Muscle layer histopathology and manometry pattern of primary esophageal motility disorders including achalasia. ( 27699951 )
2017
20
Characterization of Esophageal Motility Disorders in Children Presenting With Dysphagia Using High-Resolution Manometry. ( 28365899 )
2017
21
Exploratory Research on Latent Esophageal Motility Disorders in Dysphagia Patients. ( 28395277 )
2017
22
Rapid Drink Challenge in high-resolution manometry: an adjunctive test for detection of esophageal motility disorders. ( 27420913 )
2017
23
Esophageal motility disorders. ( 28350732 )
2017
24
High Resolution Manometry Vs Conventional Line Tracing for Esophageal Motility Disorders. ( 28539845 )
2017
25
Esophageal motility disorders-Symptomatic and manometric spectrum in Punjab, northern India. ( 28593551 )
2017
26
Peroral endoscopic myotomy (POEM) for treating esophageal motility disorders. ( 28616407 )
2017
27
Chicago Classification of Esophageal Motility Disorders: Lessons Learned. ( 28730503 )
2017
28
Trends in diagnoses after implementation of the Chicago classification for esophageal motility disorders (V3.0) for high-resolution manometry studies. ( 28881880 )
2017
29
Peroral Endoscopic Myotomy for Treating Achalasia and Esophageal Motility Disorders. ( 26717928 )
2016
30
High-Resolution Manometry Improves the Diagnosis of Esophageal Motility Disorders in Patients With Dysphagia: A Randomized Multicenter Study. ( 26832656 )
2016
31
Lymphocytic Esophagitis in Nonachalasia Primary Esophageal Motility Disorders: Improved Criteria, Prevalence, Strength of Association, and Natural History. ( 27526295 )
2016
32
A utility of peroral endoscopic myotomy (POEM) across the spectrum of esophageal motility disorders. ( 25847137 )
2016
33
Clinical Application of Esophageal High-resolution Manometry in the Diagnosis of Esophageal Motility Disorders. ( 26631942 )
2016
34
Patterns of esophageal pressure responses to a rapid drink challenge test in patients with esophageal motility disorders. ( 26686375 )
2016
35
A pictorial presentation of 3.0 Chicago Classification for esophageal motility disorders. ( 26958977 )
2016
36
Effects of Acotiamide on the Esophageal Motility Function in Patients with Esophageal Motility Disorders: A Pilot Study. ( 27326454 )
2016
37
Chicago Classification of Esophageal Motility Disorders: Applications and Limits in Adults and Pediatric Patients with Esophageal Symptoms. ( 27738966 )
2016
38
Inter-observer agreement for diagnostic classification of esophageal motility disorders defined in high-resolution manometry. ( 25185507 )
2015
39
Botulinum toxin injection for hypercontractile or spastic esophageal motility disorders: may high-resolution manometry help to select cases? ( 25212219 )
2015
40
The Chicago Classification of esophageal motility disorders, v3.0. ( 25469569 )
2015
41
Esophageal motility disorders. ( 25965124 )
2015
42
Diagnosis of Esophageal Motility Disorders: Esophageal Pressure Topography vs. Conventional Line Tracing. ( 26032151 )
2015
43
Assessment of bolus transit with intraluminal impedance measurement in patients with esophageal motility disorders. ( 26284688 )
2015
44
Relationship between esophageal clinical symptoms and manometry findings in patients with esophageal motility disorders: a cross-sectional study. ( 26793662 )
2015
45
Magnetic resonance imaging for simultaneous morphological and functional evaluation of esophageal motility disorders. ( 23689949 )
2014
46
Treatment of esophageal motility disorders based on the chicago classification. ( 25263532 )
2014
47
Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders. ( 23591282 )
2013
48
Intraoperative assessment of esophagogastric junction distensibility during per oral endoscopic myotomy (POEM) for esophageal motility disorders. ( 22955896 )
2013
49
Surgical treatment for nonspecific esophageal motility disorders. ( 23247887 )
2013
50
Outcomes of laparoscopic Nissen fundoplication in patients with manometric patterns of esophageal motility disorders. ( 23574844 )
2013

Variations for Dyskinesia of Esophagus

Expression for Dyskinesia of Esophagus

Search GEO for disease gene expression data for Dyskinesia of Esophagus.

Pathways for Dyskinesia of Esophagus

GO Terms for Dyskinesia of Esophagus

Biological processes related to Dyskinesia of Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium ion import across plasma membrane GO:1990573 9.37 ATP12A ATP4A
2 ATP hydrolysis coupled proton transport GO:0015991 9.32 ATP12A ATP4A
3 cellular sodium ion homeostasis GO:0006883 9.26 ATP12A ATP4A
4 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.16 ATP12A ATP4A
5 cellular potassium ion homeostasis GO:0030007 8.96 ATP12A ATP4A
6 sodium ion export across plasma membrane GO:0036376 8.62 ATP12A ATP4A

Molecular functions related to Dyskinesia of Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.33 CENPB TOP1 UBTF
2 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
3 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Dyskinesia of Esophagus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....